Is high-intensity focused ultrasound (HIFU) an option for neoadjuvant therapy for borderline resectable pancreatic cancer patients? – a systematic review
| Autor: | Martin Karamanliev, Tsvetomir M. Ivanov, Nadya Stanislavova, Tsanko Yotsov, Dobromir Dimitrov, Kun Zhou |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
borderline resectable
China Cancer Research medicine.medical_specialty Physiology medicine.medical_treatment pancreatic cancer Locally advanced systematic review Borderline resectable Physiology (medical) Pancreatic cancer medicine Medical technology Humans focused ultrasound surgery Stage (cooking) hifu R855-855.5 Pancreas Neoadjuvant therapy Chemotherapy business.industry medicine.disease Neoadjuvant Therapy High-intensity focused ultrasound Pancreatic Neoplasms Systematic review High-Intensity Focused Ultrasound Ablation Radiology business |
| Zdroj: | International Journal of Hyperthermia, Vol 38, Iss 2, Pp 75-80 (2021) |
| ISSN: | 1464-5157 0265-6736 |
| Popis: | Introduction Pancreatic cancer is with the poorest prognosis of all common cancers worldwide. Despite the advances in treatment the results are poor throughout the different methods. Pancreatic resection still yields the best outcome. However only a quarter of the patients present at operable stage. HIFU is a noninvasive technique that can be used to treat pancreatic cancer. Aim The aim of this review is to perform a systematic review on the data about the resection rate after HIFU ablation in patients with borderline resectable pancreatic cancer (BRPC) and the impact of this technique over the oncological results. Materials and methods The PubMed and Wanfang databases were searched using keywords: pancreatic cancer, HIFU ablation and high-intensity focused ultrasound. All found articles were reviewed. The systematic review was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) standard guidelines. This study was financially supported by 2019 'Kuan-Ren Elite' Program of 2nd Affiliated Hospital of Chongqing Medical University, China (Grant no. KY2019G019). Results The English database search showed 109 papers, of which 3 met the inclusion criteria. The Wanfang database resulted in 110 papers; however, none met the inclusion criteria of the review. From the included studies 97 patients underwent neoadjuvant HIFU ablation ± chemotherapy. Thirty-four patients reached resection (35.1%). In two patients, residual tumor (R) classification was not reported. R0 resection rate in all reported patients is 30.5% (29/95). R1 resection rate is 3.2% (3/95). Conclusion HIFU is found to be safe and feasible in locally advanced and metastatic pancreatic cancer with proven downstaging and downsizing effects. Further research on role of HIFU ablation as a neoadjuvant treatment for borderline resectable pancreatic cancer is needed. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|